NEWS: First trial of vaccine to prevent Lynch syndrome-associated cancers approved to start in Oxford Read about the Phase 1 of the INTERCEPT-Lynch trial 👇
First trial of vaccine to prevent Lynch syndrome-associated cancers approved to start in Oxford
Phase 1 of the INTERCEPT-Lynch trial, which is funded by Moderna, sponsored by the University of Oxford and run by the University's Oncology Clinical Trials Office with support from Oxford Cancer, has received authorisation from the Medicines and Healthcare products Regulatory Agency and is expected to begin recruiting participants this summer.
medsci.ox.ac.uk